Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, Wang Y, Zhang N, Xue J, Long J, Li Y, Sun H, Xun Z, Liu K, Chen X, Song Y, Yang X, Lu Z, Mao Y, Sang X, Lu Y, Zhao H. Xie F, et al. Among authors: zhao h. Front Immunol. 2022 Dec 9;13:1052937. doi: 10.3389/fimmu.2022.1052937. eCollection 2022. Front Immunol. 2022. PMID: 36569829 Free PMC article.
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y, Yang X, Wang Y, Xue J, Zhang N, Yang X, Cong N, Zhang J, Zhu C, Zhang L, Hou X, Zhao H. Wang Y, et al. Among authors: zhao h. Cancer Immunol Immunother. 2023 Jul;72(7):2197-2204. doi: 10.1007/s00262-023-03399-2. Epub 2023 Mar 1. Cancer Immunol Immunother. 2023. PMID: 36856834 Free PMC article.
36,655 results
You have reached the last available page of results. Please see the User Guide for more information.